Screening for 3-hydroxy 3-methylglutaryl-CoA (HMG-CoA) lyase deficiency was added in 2018 as part of a further expansion of the program that also included screening for severe combined immunodeficiency (SCID). Here, HMGCL is linked to severe combined immunodeficiency.